BioCentury
ARTICLE | Clinical News

Aimmune reports Phase II peanut allergy data

June 9, 2015 2:10 AM UTC

Aimmune Therapeutics Inc. (Brisbane, Calif.) reported results from the Phase II ARC001 study of AR101 to treat peanut allergy.

The company said that all 23 patients who completed treatment with AR101 met the primary endpoint of tolerating at least 443 mg of peanut protein vs. 19% of patients in the placebo arm (p≤0.0001). Additionally, 18 (78%) of the 23 patients tolerated at least 1,043 mg of peanut protein vs. zero patients in the placebo arm (p≤0.0001). ...